Balyasny Asset Management LLC Biotechnology

Balyasny Asset Management LLC

$58 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
LYEL Lyell Immunopharma, Inc.	$233M	$1.65 Million 0.0% of portfolio	1,197,576	Q3 2024 Added 21.54%
INSM Insmed Inc	$9.81B	$1.52 Million 0.0% of portfolio	20,815	Q3 2024 Reduced 87.05%
DNLI Denali Therapeutics Inc.	$3.21B	$1.31 Million 0.0% of portfolio	45,108	Q3 2024 Reduced 62.6%
CDMO Avid Bioservices, Inc.	$766M	$1.27 Million 0.0% of portfolio	111,541	Q3 2024 Added 230.16%
PHAT Phathom Pharmaceuticals, Inc.	$346M	$1.19 Million 0.0% of portfolio	65,659	Q3 2024 Added 337.55%
QURE Uni Qure N.V.	$300M	$1.15 Million 0.0% of portfolio	233,491	Q3 2024 Added 405.73%
ALT Altimmune, Inc.	$431M	$1.1 Million 0.0% of portfolio	179,940	Q3 2024 New
INCY Incyte Corp	$16B	$1.04 Million 0.0% of portfolio	15,765	Q3 2024 Added 180.07%
MRSN Mersana Therapeutics, Inc.	$230M	$1.01 Million 0.0% of portfolio	535,819	Q3 2024 New
MRNA Moderna, Inc.	$16.7B	$907,000 0.0% of portfolio	13,574	Q3 2024 Reduced 66.38%
PYXS Pyxis Oncology, Inc.	$63.9M	$825,000 0.0% of portfolio	224,957	Q3 2024 Reduced 91.22%
RCUS Arcus Biosciences, Inc.	$1.19B	$742,000 0.0% of portfolio	48,580	Q3 2024 New
EXEL Exelixis, Inc.	$11.3B	$661,000 0.0% of portfolio	25,486	Q3 2024 New
KURA Kura Oncology, Inc.	$747M	$660,000 0.0% of portfolio	33,797	Q3 2024 New
CORT Corcept Therapeutics Inc	$6.39B	$601,000 0.0% of portfolio	12,995	Q3 2024 New
EDIT Editas Medicine, Inc.	$136M	$593,000 0.0% of portfolio	174,035	Q3 2024 Added 358.38%
EYPT Eye Point Pharmaceuticals, Inc.	$285M	$535,000 0.0% of portfolio	67,073	Q3 2024 Reduced 42.28%
CABA Cabaletta Bio, Inc.	$109M	$465,000 0.0% of portfolio	98,673	Q3 2024 Added 73.63%
GERN Geron Corp	$1.49B	$444,000 0.0% of portfolio	97,837	Q3 2024 Reduced 95.5%
BMEA Biomea Fusion, Inc.	$201M	$408,000 0.0% of portfolio	40,477	Q3 2024 Added 157.83%
NKTR Nektar Therapeutics	$201M	$390,000 0.0% of portfolio	300,352	Q3 2024 Added 13.74%
URGN Uro Gen Pharma Ltd.	$281M	$363,000 0.0% of portfolio	28,612	Q3 2024 Reduced 83.55%
KALV Kal Vista Pharmaceuticals, Inc.	$239M	$312,000 0.0% of portfolio	26,968	Q3 2024 New
TYRA Tyra Biosciences, Inc.	$641M	$305,000 0.0% of portfolio	12,988	Q3 2024 New
VCEL Vericel Corp	$2.75B	$260,000 0.0% of portfolio	6,173	Q3 2024 Reduced 82.3%
ZNTL Zentalis Pharmaceuticals, Inc.	$191M	$251,000 0.0% of portfolio	68,662	Q3 2024 Added 70.75%
RVNC Revance Therapeutics, Inc.	$212M	$247,000 0.0% of portfolio	96,154	Q3 2024 New
IBRX Immunity Bio, Inc.	$1.83B	$244,000 0.0% of portfolio	65,811	Q3 2024 Reduced 68.24%
IDYA Ideaya Biosciences, Inc.	$1.28B	$240,000 0.0% of portfolio	7,605	Q3 2024 New
CAPR Capricor Therapeutics, Inc.	$400M	$228,000 0.0% of portfolio	14,999	Q3 2024 New
NUVB Nuvation Bio Inc.	$628M	$220,000 0.0% of portfolio	95,725	Q3 2024 New
XLO Xilio Therapeutics, Inc.	$28.3M	$215,000 0.0% of portfolio	272,486	Q2 2024 Reduced 19.51%
COGT Cogent Biosciences, Inc.	$604M	$206,000 0.0% of portfolio	19,118	Q3 2024 Reduced 56.98%
VERV Verve Therapeutics, Inc.	$420M	$205,000 0.0% of portfolio	42,415	Q3 2024 Reduced 52.48%
VIR Vir Biotechnology, Inc.	$1.22B	$197,000 0.0% of portfolio	26,433	Q3 2024 New
AMLX Amylyx Pharmaceuticals, Inc.	$315M	$164,000 0.0% of portfolio	50,903	Q3 2024 Added 122.41%
ABSI Absci Corp	$278M	$129,000 0.0% of portfolio	33,977	Q3 2024 New
CCCC C4 Therapeutics, Inc.	$199M	$112,000 0.0% of portfolio	19,744	Q3 2024 Reduced 98.98%
SANA Sana Biotechnology, Inc.	$489M	$78,000 0.0% of portfolio	18,873	Q3 2024 New
FULC Fulcrum Therapeutics, Inc.	$196M	$37,000 0.0% of portfolio	10,374	Q3 2024 Reduced 8.74%
PROK Prokidney Corp Ord Shs Cl A(Cy	$119M	$24,000 0.0% of portfolio	12,578	Q3 2024 New
AVTE Aerovate Therapeutics, Inc.	$64.1M	$21,000 0.0% of portfolio	10,235	Q3 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	22,518	Q3 2024 Reduced 14.49%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.